A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors Meeting Abstract
| Authors: | Juric, D.; Kalinsky, K.; Oliveira, M.; Cervantes, A.; Bedard, P.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; Italiano, A.; Saura, C.; Gambardella, V.; Veitch, Z.; Dickmann, L.; Kotani, N.; Fredrickson, J.; Kapp, A.; Hutchinson, K.; Royer-Joo, S.; Vaze, A.; Schutzman, J.; Jhaveri, K. |
| Abstract Title: | A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500099 |
| DOI: | 10.1158/1538-7445.Sabcs19-ot1-08-04 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-08-04 -- Source: Wos |
